Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohort

Sánchez, Alejandro; Rodríguez, Dayron; Allard, Christopher B.; Bechis, Seth K.; Sullivan, Ryan J.; Boeke, Caroline E.; Kuppermann, David; Cheng, Jed-Sian; Barrisford, Glen W.; Preston, Mark A.; Feldman, Adam S.

doi:10.1016/j.urolonc.2015.11.009

Cited by 62 publications

(56 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 In our study, a combination of NGS (covering exons [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] and Sanger sequencing (covering exons 11 and 15) was used. Although some of the earlier studies had smaller sample sizes, we doubt this alone could account for such discrepancy.…”

Section: Molecular Targetsmentioning

confidence: 99%

“…1,3 Compared with cutaneous and other types of mucosal nongynecologic melanoma (NGM), the overall prognosis for patients with vulvovaginal melanoma (VVM) is poor. 4,7,8 Unfortunately, because 40% of women with VVM reportedly present with regional or distant metastasis, 2 the late stage at diagnosis and high incidence of drug resistance 1 portend a poor prognosis. [4][5][6] Before the era of targeted molecular therapies, treatment options for VVM broadly included surgery, chemotherapy, and/or radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma

Hou

Baptiste

Hombalegowda

et al. 2016

Cancer

110

View full text Add to dashboard Cite

show abstract

Section: Molecular Targetsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma

Hou

Baptiste

Hombalegowda

et al. 2016

Cancer

110

View full text Add to dashboard Cite

show abstract

“…Among the factors that determine prognosis are older age, male gender, depth greater than 1 mm, superficial ulceration, high mitotic index and presence of S100 protein. However, at presentation, 36.5% of men presented with regional or distant disease as our patients [1,2].…”

Section: Discussionmentioning

confidence: 77%

“…It occurs most frequently in sun-exposed areas, being much less common in the genitourinary location (0.1-0.2% of all melanomas), with higher incidence in Caucasians and women [1]. With regard to genitourinary melanoma, the scrotum is the rarest location of prevalence, with only 20 cases being reported so far (table 1).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Scrotum Melanoma: Evolution Over One Year in This Unusual Location

Zucchet¹,

García²,

Soriano³

et al. 2016

Urol Int

View full text Add to dashboard Cite

Genitourinary melanoma accounts for 0.1-0.2% of melanoma, the scrotum being its rarest location. We report about an 85-year-old patient who was referred to our outpatient clinic due to the presence of a scrotum black papule for 20 months. Wide local excision was performed, and histology revealed a malignant melanoma. Chest and abdominal CT revealed metastatic disease, so chemotherapy, immunotherapy and radiotherapy were administered. We describe the evolution over 1 year in this unusual location, as well as complications and the currently available therapeutic options to cure this disease.

show abstract

Efficacy and safety of carbon‐ion radiotherapy for the malignant melanoma: A systematic review

Zhang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Malignant melanomas (MMs) originate from melanocytes in the basal layer of the epidermis, and they are characterized by high malignancy, early metastasis, poor prognosis, and high mortality. Depending on their location, MMs can be classified as cutaneous, uveal or mucosal. Previous studies suggest that average morbidity rates are 16.2 per 100 000 in the United States and 0.383 per 100 000 in Japan. 1 However, MMs incidence increased continuously worldwide. 2,3 MMs were the fifth most common cancer in men and the sixth most common cancer in women in 2018. According to the American Association of Cancer (AJCC) TNM staging system, the 5-year overall survival (5-y OS) rates are approximately 98.2% in patients at stages I/II, 61.7% at stage III, and 15.2% at stage IV. 4 Although stage I MMs are typically associated with good prognoses after surgical treatment only, achieving negative margins in all patients was difficult. Currently available treatment options for patients with MM include radiotherapy (RT), chemotherapy, targeted therapy, and immunotherapy. Adjuvant therapies were

show abstract

Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohort

Cited by 62 publications

References 17 publications

Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma

Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma

Scrotum Melanoma: Evolution Over One Year in This Unusual Location

Efficacy and safety of carbon‐ion radiotherapy for the malignant melanoma: A systematic review

Contact Info

Product

Resources

About